CXADR and enterovirus infectious disease: So far treatment options for enterovirus infections are limited and include application of monoclonal antibodies as shown for causative agents of HFMD [54] and for coxsackievirus [55] in addition to the therapeutic potential of the soluble analogue of the receptor CAR [56].